Erythropoietin delays disease onset in an amyotrophic lateral sclerosis model

Erythropoietin (Epo) has been shown in the recent years to have neuroprotective activity in a variety of settings. In this study, we investigated its impact on the progression of paralysis in a mouse model simulating the human disorder amyotrophic lateral sclerosis (ALS). We found that Epo can delay the onset of motor deterioration in transgenic SOD G93A mice without prolonging their survival. Notably this effect was selective for the females only. These initial findings encourage further investigation of this biological avenue in the search for improved remedies for this fatal disease.

[1]  Michael M. Wang,et al.  Sex differences in cell death , 2005, Annals of neurology.

[2]  L. Bruijn,et al.  Unraveling the mechanisms involved in motor neuron degeneration in ALS. , 2004, Annual review of neuroscience.

[3]  P Ghezzi,et al.  Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[4]  Z. Erbayraktar,et al.  Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[5]  M. Gurney,et al.  Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. , 1994, Science.

[6]  P. Carmeliet,et al.  VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death , 2003, Nature Genetics.

[7]  P. Lewczuk,et al.  Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[8]  G. Rotilio,et al.  Neurodegeneration in amyotrophic lateral sclerosis: the role of oxidative stress and altered homeostasis of metals , 2003, Brain Research Bulletin.

[9]  J. Veldink,et al.  Sexual differences in onset of disease and response to exercise in a transgenic model of ALS , 2003, Neuromuscular Disorders.

[10]  Z. Erbayraktar,et al.  Derivatives of Erythropoietin That Are Tissue Protective But Not Erythropoietic , 2004, Science.

[11]  P. Lewczuk,et al.  Erythropoietin Therapy for Acute Stroke Is Both Safe and Beneficial , 2002, Molecular medicine.

[12]  M. Farooque,et al.  Gender-related differences in recovery of locomotor function after spinal cord injury in mice , 2006, Spinal Cord.

[13]  R. Holman,et al.  Amyotrophic Lateral Sclerosis Mortality in the United States, 1979–2001 , 2005, Neuroepidemiology.

[14]  J. Möcks,et al.  The safety of treatment with recombinant human erythropoietin in clinical use: a review of controlled studies. , 1998, International journal of molecular medicine.

[15]  S H Appel,et al.  Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. , 1995, Brain : a journal of neurology.

[16]  A. Cerami,et al.  Emerging biological roles for erythropoietin in the nervous system , 2005, Nature Reviews Neuroscience.

[17]  T D Koepsell,et al.  Prognosis in amyotrophic lateral sclerosis , 2003, Neurology.

[18]  A. Cerami,et al.  Erythropoietin prevents motor neuron apoptosis and neurologic disability in experimental spinal cord ischemic injury , 2002, Proceedings of the National Academy of Sciences of the United States of America.